Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian H Kushner

Showing results (61-70 of 103) with videos related to

Pageof 11
Sort By:
Cancers|December 24, 2021
Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk NeuroblastomaFiorella Iglesias Cardenas, Audrey Mauguen, Irene Y Cheung, et al.
JAMA Oncology|December 22, 2022
Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical TrialIrene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.
International Journal of Radiation Oncology, Biology, Physics|February 15, 2018
Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?Dana L Casey, Ken L Pitter, Brian H Kushner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2025
A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete RemissionBrian H Kushner, Shakeel Modak, Audrey Mauguen, et al.
Cancer|April 3, 2014
Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary eraBrian H Kushner, Shakeel Modak, Kim Kramer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 9, 2016
Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II StudyShakeel Modak, Pat Zanzonico, Jorge A Carrasquillo, et al.
Pediatric Blood & Cancer|November 2, 2007
Brain-sparing radiotherapy for neuroblastoma skull metastasesSuzanne L Wolden, Christopher A Barker, Brian H Kushner, et al.
Sarcoma|May 7, 2015
Myeloablative chemotherapy with autologous stem cell transplant for desmoplastic small round cell tumorChristopher J Forlenza, Brian H Kushner, Nancy Kernan, et al.
Journal of Pediatric Surgery|March 16, 2004
The impact of gross total resection on local control and survival in high-risk neuroblastomaMichael P La Quaglia, Brian H Kushner, Wendy Su, et al.
Pediatric Blood & Cancer|March 10, 2010
Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastomaSonal Bhandari, Nai-Kong V Cheung, Brian H Kushner, et al.
Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
Cancers|December 24, 2021
Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk NeuroblastomaFiorella Iglesias Cardenas, Audrey Mauguen, Irene Y Cheung, et al.
JAMA Oncology|December 22, 2022
Effect of Oral β-Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical TrialIrene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.
International Journal of Radiation Oncology, Biology, Physics|February 15, 2018
Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?Dana L Casey, Ken L Pitter, Brian H Kushner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2025
A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete RemissionBrian H Kushner, Shakeel Modak, Audrey Mauguen, et al.
Cancer|April 3, 2014
Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary eraBrian H Kushner, Shakeel Modak, Kim Kramer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 9, 2016
Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II StudyShakeel Modak, Pat Zanzonico, Jorge A Carrasquillo, et al.
Pediatric Blood & Cancer|November 2, 2007
Brain-sparing radiotherapy for neuroblastoma skull metastasesSuzanne L Wolden, Christopher A Barker, Brian H Kushner, et al.
Sarcoma|May 7, 2015
Myeloablative chemotherapy with autologous stem cell transplant for desmoplastic small round cell tumorChristopher J Forlenza, Brian H Kushner, Nancy Kernan, et al.
Journal of Pediatric Surgery|March 16, 2004
The impact of gross total resection on local control and survival in high-risk neuroblastomaMichael P La Quaglia, Brian H Kushner, Wendy Su, et al.
Pediatric Blood & Cancer|March 10, 2010
Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastomaSonal Bhandari, Nai-Kong V Cheung, Brian H Kushner, et al.
Pageof 11